Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy

Xiao, Yang; Li, Jun; Liu, Yangchen; Huang, Xin-En; Guo, Jian-Xong; Wei, Wei

doi:10.7314/apjcp.2014.15.9.3951

Cited by 10 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A terapia antiemética tem como principal objetivo impedir a náusea, seja ela aguda (nas primeiras 24 horas após a quimioterapia), tardia (após as primeiras 24 horas) ou antecipatória (antes da administração do tratamento) (5)(6) . O medicamento pode ser administrado antes da infusão do quimioterápico ou repetido em intervalos programados (5,7) . No caso de uma profilaxia emética ineficaz, as náuseas e vômitos agudos podem aparecer nas primeiras duas horas após o início do antineoplásico (6) .…”

Section: Introductionunclassified

See 1 more Smart Citation

Quality of life and people using antineoplastic agents: a descriptive study

Sá

Rodrigues

Oliveira

et al. 2014

Online Brazilian Journal of Nursing

View full text Add to dashboard Cite

RESUMOObjetivos: avaliar a qualidade de vida das pessoas que apresentaram náuseas e vômitos induzidos por antineoplásicos e correlacionar a qualidade de vida com o potencial emetogênico do protocolo quimioterápico e com o dimensionamento do esquema antiemético. Método: estudo descritivo, quantitativo, realizado em um ambulatório de onco-hematologia de um hospital do município de São Paulo. Foi utilizado o questionário SF-36 para avaliar a qualidade de vida dos indivíduos e um questionário de caracterização da população. Resultados: a maior parte dos participantes do sexo feminino (70%), com idade entre 60 a 69 anos (33%), apresentava câncer ginecológico (30%) e realizava tratamento com protocolo de moderado potencial emetogênico (70%). Discussão: constatou-se comprometimento em todos os domínios de qualidade de vida avaliados. Não houve diferença significativa quando comparados os potenciais emetogênicos e os dimensionamentos antieméticos. Conclusão: os domínios de qualidade de vida mais afetados nesses indivíduos foram a limitação física e a vitalidade.

show abstract

Section: Introductionunclassified

“…O controle inadequado é o principal fator de risco para o aparecimento de sintomas tardios, que podem durar de três a quatro dias. O principal fator para as náuseas antecipatórias é o aparecimento destes sintomas agudos e tardios, principalmente no primeiro ciclo de quimioterapia (6)(7) .…”

Section: Introductionunclassified

Quality of life and people using antineoplastic agents: a descriptive study

Sá

Rodrigues

Oliveira

et al. 2014

Online Brazilian Journal of Nursing

View full text Add to dashboard Cite

show abstract

“…Analysis was performed using Statistica version 8.0 software (StatSoft Inc., Tulsa, OK) with p<0.05 described as statistically significant. We have enough experience in conducting medical researches, and have published some results elsewhere (Qian et al, 2014;Ji et al, 2014;Huang et al, 2014;Wu et al, 2014;Xiao et al, 2014;Lu et al, 2014;Xu et al, 2014;Gong et al, 2014;Wu et al, 2013;. …”

Section: Discussionmentioning

confidence: 99%

Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy

Huang²

2015

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

“…Stata version 8.0 (StatSoft Inc., Tulsa, OK) was used to analyze data. We have enough experience in conducting medical researches, and have published some results elsewhere Wei et al, 2013;Wu et al, 2013;Gong et al, 2014;Lu et al, 2014;Xiao et al, 2014;Xu et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer

Wu¹,

Huang²,

Cao³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

. Nevertheless, many patients still failed to treatment due to tumor recurrence and metastasis, and 5-year survival rate still less than 10%.Pemetrexed is a new anticancer drug. 2 by 10 minute infusion on day 1, repeated every 3 weeks. Doses were modified depending on nadir counts of blood cells. Combined chemotherapeutic agents included irinotecan, lobaplatin, carboplatin, oxaliplatin, gemcitabine, cis-platinum or bevacizumab. Multiple variables (age, sex, hemoglobin, platinum drugs combined, metastasis sites, LDH, ALP, CEA>40 ug/ml) reported earlier were selected.We used logistic regression analysis to evaluate relationships between these and tumor response. Results: On multivariable analysis, we found that age was significant in predicting the responsiveness to pemetrexed (p<0.05) combined with oxaliplatin. We did not find any other factors which were significantly associated with the response rate to chemotherapy with pemetrexed and irinotecan. Conclusions: By multivariate analysis, we found that age had significant impact on the responsiveness of pemetrexed when combined with oxaliplatin. Additional research based on genomic properties of host and tumors are needed to clarify markers for better selection of patients who could benefit from pemetrexed combined chemotherapy.

show abstract

Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy

Cited by 10 publications

References 24 publications

Quality of life and people using antineoplastic agents: a descriptive study

Quality of life and people using antineoplastic agents: a descriptive study

Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy

A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer

Contact Info

Product

Resources

About